We advised Nanoform, an innovative company that specialises in nanoparticle production for medicinal purposes, on a private placement totaling EUR 10 million. The Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acted as anchor investors.
The investment will enable Nanoform to meet the growing demand for nanonised drug compounds with increased solubility and bioavailability. The private placement follows the rapid construction of Nanoform’s first GMP manufacturing plant. Finalising the construction of the plant, and building a second GMP facility, will help accelerate the development of more efficient therapies by significantly increasing the number of nanonised materials that will proceed to clinical trials.